A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: Design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial

Journal of Cardiovascular Medicine

Volumn 9, Issue 9, 2008, Pages 957-962

  Biondi Zoccai, Giuseppe G L ^a   Valgimigli, Marco ^b,c   Sheiban, Imad ^a   Margheri, Massimo ^d   Marzocchi, Antonio ^e   Prati, Francesco ^f   Vischi, Massimo ^g   Lettieri, Corrado ^h   Violini, Roberto ⁱ   Sardella, Gennaro ^j   Stabile, Amerigo ^k   Clementi, Fabrizio ^k   Romeo, Francesco ^k   Colombo, Antonio ^l,m   Sangiorgi, Giuseppe ^k,l,m  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c IRCCS   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h CARLO POMA HOSPITAL   (Italy)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m EMO GVM CENTRO CUORE COLUMBUS   (Italy)

more..

Author keywords

Drug eluting stent; Glycoprotein ilb iiia inhibitors; Percutaneous coronary intervention; Study design

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; CYPHER; ENDEAVOR; EPTIFIBATIDE; HEPARIN; PLACEBO; PROMUS; TROPONIN; UNCLASSIFIED DRUG; XIENCE V; ANTITHROMBOCYTIC AGENT; CREATINE KINASE MB; FIBRINOGEN RECEPTOR; PEPTIDE;

ADD ON THERAPY; ADULT; ANATOMY; ARTICLE; BLEEDING; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HOSPITAL; HUMAN; IMPLANTATION; INTROSPECTION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESTENOSIS; REVASCULARIZATION; TELEPHONE; BIOASSAY; DRUG ANTAGONISM; METHODOLOGY; SINGLE BLIND PROCEDURE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG-ELUTING STENTS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SINGLE-BLIND METHOD;

EID: 55249123634     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282ffd3a6     Document Type: Article

References (20)

1. Karvouni E, Katritsis DG, loannidis JP. Intravenous glycoprotein Ilb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41:26-32.
2. Brophy JM, Joseph L. Medical decision making with incomplete evidence: choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions. Med Decis Making 2005; 25:222-228.
3. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicenter randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354:2019-2024.
4. O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, et al., ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618-621.
5. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F,ten Berg JM, et al., Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232-238.
6. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, et al., Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110:3627-3635.
7. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 111:2099-2106.
8. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation 2005; 111 :1153- 1159.
9. Lotrionte M, Biondi-Zoccai G, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, et al. Metaanalysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100:1199-1206.
10. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al., IntracoronaryStenting and Antithrombotic: Regimen Rapid EarlyAction for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531 -1538.
11. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al., STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-met al stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293:2109-2117.
12. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al., For the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804-847.
13. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. JAm Coll Cardiol 2004; 44:14-19.
14. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, et al. Randomized comparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106:1470-1476.
15. Biondi-Zoccai GGL, Sangiorgi GM, Chieffo A, Vittori G, Falchetti E, Margheri M, et al., RECIPE (Real-world Eluting-stent Comparative Italian retrosPective Evaluation) Study Investigators. Validation of predictors of intraprocedural stentthrombosisin the drug-eluting stentera. Am J Cardiol 2005; 95:1466-1468.
16. Orlic D, Bonizzoni E, Stankovic G, Airoldi F, Chieffo A, Corvaja N, et al. Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol 2004; 43:1154-1160.
17. Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005; 45:1570-1573.
18. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, et al., On behalf of the Italian 'Atherosclerosis, Thrombosis, and Vascular Biology' and 'Society for Invasive Cardiology: GISE' Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J2005; 26:789-794.
19. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damageduring coronaryintervention: resultsfrom theARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110:674-678.
20. Teirstein PS, KaoJ, WatkinsM, Tannenbaum MA, Laufer N, Chang M, et al. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol 2005; 96:500-505.